Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context
CAR-T cell therapy has revolutionized immunotherapy but its allogeneic application, using various strategies, faces significant challenges including graft-versus-host disease and graft rejection. Recent advances using Virus Specific T cells to generate CAR-VST have demonstrated potential for enhance...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1527648/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527918984953856 |
|---|---|
| author | Valentine Wang Barbara Savoldo José-Arthur Guimaraes Gianpietro Dotti Loïc Reppel Loïc Reppel Danièle Bensoussan Danièle Bensoussan |
| author_facet | Valentine Wang Barbara Savoldo José-Arthur Guimaraes Gianpietro Dotti Loïc Reppel Loïc Reppel Danièle Bensoussan Danièle Bensoussan |
| author_sort | Valentine Wang |
| collection | DOAJ |
| description | CAR-T cell therapy has revolutionized immunotherapy but its allogeneic application, using various strategies, faces significant challenges including graft-versus-host disease and graft rejection. Recent advances using Virus Specific T cells to generate CAR-VST have demonstrated potential for enhanced persistence and antitumor efficacy, positioning CAR-VSTs as a promising alternative to conventional CAR-T cells in an allogeneic setting. This review provides a comprehensive overview of CAR-VST development, emphasizing strategies to mitigate immunogenicity, such as using a specialized TCR, and approaches to improve therapeutic persistence against host immune responses. In this review, we discuss the production methods of CAR-VSTs and explore optimization strategies to enhance their functionality, activation profiles, memory persistence, and exhaustion resistance. Emphasis is placed on their unique dual specificity for both antitumor and antiviral responses, along with an in-depth examination of preclinical and clinical outcomes. We highlight how these advances contribute to the efficacy and durability of CAR-VSTs in therapeutic settings, offering new perspectives for broad clinical applications. By focusing on the key mechanisms that enable CAR-VSTs to address autologous CAR-T cell challenges, this review highlights their potential as a promising strategy for developing effective allogeneic CAR-T therapies. |
| format | Article |
| id | doaj-art-a805dd6556934b5bbf213910e629a61f |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-a805dd6556934b5bbf213910e629a61f2025-01-15T05:11:08ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.15276481527648Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral contextValentine Wang0Barbara Savoldo1José-Arthur Guimaraes2Gianpietro Dotti3Loïc Reppel4Loïc Reppel5Danièle Bensoussan6Danièle Bensoussan7Unité Mixte de Recherche (UMR) 7365 Centre National de la Recherche Scientifique (CNRS), Ingénierie Moléculaire, Cellulaire et Physiopathologie (IMoPA), Université de Lorraine, Nancy, FranceLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, United StatesUnité Mixte de Recherche (UMR) 7365 Centre National de la Recherche Scientifique (CNRS), Ingénierie Moléculaire, Cellulaire et Physiopathologie (IMoPA), Université de Lorraine, Nancy, FranceLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, United StatesUnité Mixte de Recherche (UMR) 7365 Centre National de la Recherche Scientifique (CNRS), Ingénierie Moléculaire, Cellulaire et Physiopathologie (IMoPA), Université de Lorraine, Nancy, FranceCentre Hospitalier Régional Universitaire (CHRU) Nancy, Cell Therapy and Tissue Bank Unit, MTInov Bioproduction and Biotherapy Integrator, Nancy, FranceUnité Mixte de Recherche (UMR) 7365 Centre National de la Recherche Scientifique (CNRS), Ingénierie Moléculaire, Cellulaire et Physiopathologie (IMoPA), Université de Lorraine, Nancy, FranceCentre Hospitalier Régional Universitaire (CHRU) Nancy, Cell Therapy and Tissue Bank Unit, MTInov Bioproduction and Biotherapy Integrator, Nancy, FranceCAR-T cell therapy has revolutionized immunotherapy but its allogeneic application, using various strategies, faces significant challenges including graft-versus-host disease and graft rejection. Recent advances using Virus Specific T cells to generate CAR-VST have demonstrated potential for enhanced persistence and antitumor efficacy, positioning CAR-VSTs as a promising alternative to conventional CAR-T cells in an allogeneic setting. This review provides a comprehensive overview of CAR-VST development, emphasizing strategies to mitigate immunogenicity, such as using a specialized TCR, and approaches to improve therapeutic persistence against host immune responses. In this review, we discuss the production methods of CAR-VSTs and explore optimization strategies to enhance their functionality, activation profiles, memory persistence, and exhaustion resistance. Emphasis is placed on their unique dual specificity for both antitumor and antiviral responses, along with an in-depth examination of preclinical and clinical outcomes. We highlight how these advances contribute to the efficacy and durability of CAR-VSTs in therapeutic settings, offering new perspectives for broad clinical applications. By focusing on the key mechanisms that enable CAR-VSTs to address autologous CAR-T cell challenges, this review highlights their potential as a promising strategy for developing effective allogeneic CAR-T therapies.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1527648/fullCAR-Tvirus specific T cellCAR-VSTallogeneicGvHDgraft rejection |
| spellingShingle | Valentine Wang Barbara Savoldo José-Arthur Guimaraes Gianpietro Dotti Loïc Reppel Loïc Reppel Danièle Bensoussan Danièle Bensoussan Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context Frontiers in Immunology CAR-T virus specific T cell CAR-VST allogeneic GvHD graft rejection |
| title | Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context |
| title_full | Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context |
| title_fullStr | Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context |
| title_full_unstemmed | Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context |
| title_short | Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context |
| title_sort | alloreactive free car vst therapy a step forward in long term tumor control in viral context |
| topic | CAR-T virus specific T cell CAR-VST allogeneic GvHD graft rejection |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1527648/full |
| work_keys_str_mv | AT valentinewang alloreactivefreecarvsttherapyastepforwardinlongtermtumorcontrolinviralcontext AT barbarasavoldo alloreactivefreecarvsttherapyastepforwardinlongtermtumorcontrolinviralcontext AT josearthurguimaraes alloreactivefreecarvsttherapyastepforwardinlongtermtumorcontrolinviralcontext AT gianpietrodotti alloreactivefreecarvsttherapyastepforwardinlongtermtumorcontrolinviralcontext AT loicreppel alloreactivefreecarvsttherapyastepforwardinlongtermtumorcontrolinviralcontext AT loicreppel alloreactivefreecarvsttherapyastepforwardinlongtermtumorcontrolinviralcontext AT danielebensoussan alloreactivefreecarvsttherapyastepforwardinlongtermtumorcontrolinviralcontext AT danielebensoussan alloreactivefreecarvsttherapyastepforwardinlongtermtumorcontrolinviralcontext |